|Bid||1,478.56 x 49400|
|Ask||1,511.36 x 13500|
|Day's range||1,465.25 - 1,465.25|
|52-week range||1,396.85 - 1,784.91|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||33.20|
|Forward dividend & yield||51.81 (3.54%)|
|Ex-dividend date||14 Sept 2021|
|1y target est||N/A|
Merck (NYSE:MRK) looks like it has bottomed out and set to potentially enter a bull run. We are going to take a look at how well has Merck been investing funds, and do the fundamentals present a baseline from which the company can grow.
Dr. Cedric Dark, Assistant Professor at Baylor College of Medicine & Board Member with Doctors for America, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.